The Biden administration has announced the next 15 drugs chosen for Medicare negotiation, marking one of its final acts ...

Monday, three Big Pharma leaders took center stage and addressed concerns about future patent expirations head-on.

Biopharma executives make their predictions for the year ahead, from a bold forecast for the return of the megadeal to a plea ...

Bristol Myers Squibb plans to release initial late-stage trial data on Cobenfy in Alzheimer’s-related psychosis during the ...

Analyst David Risinger of Leerink Partners reiterated a Buy rating on Bristol-Myers Squibb (BMY – Research Report), retaining the price target ...

Arsenal Biosciences, Inc., a clinical-stage programmable cell therapy company, announced Monday that drug maker Bristol-Myers Squibb ...

Bristol Myers Squibb announced that it has been named in the prestigious Dow Jones Sustainability Index (DJSI) for the second ...

Bristol Myers Squibb CEO Chris Boerner described his company's new drug, Cobenfy, which can be used to treat psychiatric disorders like schizophrenia. He said the treatment is effective but doesn ...

Its clinical pipeline includes treatments for kidney cancer and preclinical candidates for prostate cancer and other solid tumors, in addition to the partnered programs with Bristol Myers Squibb.

The pharma will spend up to $2.5 billion to acquire an experimental PI3K inhibitor from Scorpion, which will spin out a new ...